NCT00396721

Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy

Pilot Trial of Treatment of Poor-Prognosis IgA Nephropathy With Low Exposure to Sirolimus.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Josep m Cruzado · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test in a pilot trial the efficacy and tolerance of sirolimus oral (at low doses) in patient to treat poor-prognosis IgA Nephropathy.

Conditions

• Glomerulonephritis, IGA
• Nephropathy, IGA
• IGA Nephropathy

Interventions

Type	Name	Description
DRUG	ACE inhibitor + statin	sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d
DRUG	Sirolimus (study drug)+ACE inhibitor + statin	enalapril starting at 5 mg/d in order to control blood pressure. Atorvastatin starting at 10 mg/d

Timeline

• Start date: 2006-01-01
• Primary completion: 2009-10-01
• Completion: 2010-02-01
• First posted: 2006-11-07
• Last updated: 2011-09-16

Locations

1 site across 1 country: Spain